US-based Implant Sciences Corporation (IMSC) has delivered its first shipment of QS-B220 desktop explosives trace detectors (ETDs) to several US airports.
The delivery was part of a contract awarded by US Transportation Security Administration (TSA) in November, 2014 to deliver 1,170 units to enhance the security operations at airports across the nation.
The QS-B220 trace detection systems incorporates the company's patented non-radioactive ion mobility spectrometry (IMS) analysis technology enabling it to perform real-time detection and identification of trace amounts of different military, commercial and homemade explosives, as well as illicit drugs.
Equipped with a patented inCal internal automatic calibration system, the solution minimises errors that could result from an uncalibrated instrument.
Additionally, the solution features a radioactive material-free design, easy-to-use touchscreen user interface, push-button maintenance and diagnostics.
The company claims that QS-B220 can be deployed for a much lower total cost of ownership than other approved products with its significantly lower maintenance requirements than its competing systems.
IMSC Americas general manager Todd Swearingen said: "We are pleased to accommodate TSA's preferred delivery schedule for this shipment. As an American company, the fact that our QS-B220 ETDs are being deployed across the US and will provide valuable protection to passengers represents the accomplishment of a major milestone.
"Implant Sciences is honoured to have been selected by TSA and we look forward to enhancing security operations across US airports. This has been an important goal for the company for many years now, and we are extremely proud of this success."
Similar ETDs are currently in use at airports in Austria and Germany.